Elmar Kraus
Stock Analyst at DZ Bank
(2.92)
# 1,507
Out of 4,886 analysts
12
Total ratings
80%
Success rate
25.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Elmar Kraus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Hold | $820 | $772.87 | +6.10% | 4 | Feb 21, 2024 | |
| GSK GSK plc | Downgrades: Hold | n/a | $38.19 | - | 1 | Feb 11, 2022 | |
| AZN AstraZeneca | Upgrades: Hold | n/a | $69.63 | - | 1 | Feb 11, 2022 | |
| PFE Pfizer | Upgrades: Buy | $41 | $25.24 | +62.44% | 2 | Feb 4, 2021 | |
| MDT Medtronic | Downgrades: Hold | $92 | $87.67 | +4.94% | 2 | May 14, 2020 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $111.78 | - | 2 | Mar 18, 2020 | |
Eli Lilly and Company
Feb 21, 2024
Downgrades: Hold
Price Target: $820
Current: $772.87
Upside: +6.10%
GSK plc
Feb 11, 2022
Downgrades: Hold
Price Target: n/a
Current: $38.19
Upside: -
AstraZeneca
Feb 11, 2022
Upgrades: Hold
Price Target: n/a
Current: $69.63
Upside: -
Pfizer
Feb 4, 2021
Upgrades: Buy
Price Target: $41
Current: $25.24
Upside: +62.44%
Medtronic
May 14, 2020
Downgrades: Hold
Price Target: $92
Current: $87.67
Upside: +4.94%
Gilead Sciences
Mar 18, 2020
Upgrades: Buy
Price Target: n/a
Current: $111.78
Upside: -